私たちの仕事、それは何百万、何千万というからだのデータを通して、そして医療の現場で、人々の健康を見守っている仕事です。その仕事は、表に見る仕事ではないけれど、今日も人々と医療の間で健康を支えている。私たちには、私たちだけが見える未来があります。それはたくさんのデータが教えてくれる、いのちの未来。大きな世の中の変化の中で、私たちにしかつくることができない、健康の未来。私たちは、見つけたい。誰もが健康で長く生きられる社会のために、まだ誰も気づいていない、人間のからだの可能性を。私たちは、動きだす。見守るだけではなく、何が大切かを自ら見つけて、人々と医療の進歩を、確かな信頼でつなげていくために。

人と医療のまんなかで、変わらない使命のために、私たちはひとつになって、変わらぬに続く。

Our pursuit is to champion public health through products and services empowered by leading-edge technology. Often without recognition, we support and inspire patients, medical professionals, and society as a whole with daily medical solutions.

We envision a future that others can’t, through insights derived from data. Our unique perspective helps us provide innovative solutions that contribute to a thriving tomorrow.

We believe it is our duty to contribute to a society where anyone can live a long and fruitful life, as we discover new possibilities for human health.

We’ve set a revolution into motion, seeking meaningful answers to build trust and bridge humanity and healthcare services.

Even as we evolve, our promise remains steadfast as we strive to meet tomorrow’s ever-changing and diverse medical needs.
The Miraca Group is transforming itself into an integrated healthcare group that creates new value with a focus on clinical laboratory testing.

Acutely aware that a human life is behind every sample and test, the Miraca Group has been enhancing the quality of clinical laboratory testing and providing superior diagnostic products and services for more than 50 years.

Miraca Group companies used to manage their businesses individually by utilizing each company’s strengths. However, in 2017 we decided to move to a new phase as an integrated healthcare group.

We will leverage Group synergies and create totally new value as a healthcare group that has strength in the clinical laboratory testing field.

Second growth phase of the Miraca Group

The Miraca Group is transforming itself into an integrated healthcare group with a focus on the fields of clinical laboratory testing and in vitro diagnostics.
As the bridge between people and healthcare, the Miraca Group is realizing a healthier future for all.

Through our clinical laboratory testing business and the development, manufacture and sale of diagnostic reagents and equipment we will create Group synergies by fusing the various technologies and knowledge of Group companies.

Leveraging these synergies to ensure that people can have trust in medical progress—this is what we strive to achieve.

Medical institutions

We serve as a bridge that enables superior healthcare through clinical testing. We provide a comprehensive array of services that ranges from providing testing reagents and instruments to contract testing, management of in-hospital laboratory operation and consulting.

Comprehensive support

Research institutions

Creation of innovative services

We bring together the Group’s basic research capabilities and promote open innovation in our basic research and existing businesses with academia and research institutions to develop the seeds for new products and services.

Companies

Creation of new business opportunities

We aim to develop new businesses through approaches including the fusion of healthcare and information technology, helping pharmaceutical companies develop new drugs, and forming alliances with healthcare companies.

Patients

Consumers

Society

In Vitro Diagnostics

Clinical Laboratory Testing

Healthcare Related Sterilization & Related services

Emerging New Business & others

Miraca Group Corporate Profile
Bridging People to Healthcare
We continuously strive to be an integrated healthcare group that delivers new value.

The healthcare environment in Japan is changing rapidly. Reducing medical expenses in an aging society is an urgent issue, and preventive care has become increasingly important. In addition, advanced technologies such as artificial intelligence (AI) and use of big data are expanding the possibilities of healthcare. Healthcare is evolving, and the role of clinical laboratory testing is expanding beyond diagnosis and health management to include treatment policy decisions, disease prevention and extension of healthy life expectancy.

Given these circumstances, the role of the Miraca Group is growing in importance, as we have capabilities in both clinical laboratory testing service and development, manufacture and sale of diagnostic products. Utilizing our expertise, we are totally committed to delivering even greater value.

The Miraca Group has therefore positioned the year 2017 as the commencement of second phase growth. We will develop new products and improve our services by integrating the Group and leveraging Group synergies to meld our expertise in our particular markets with the comprehensive strengths of the entire Group.

We strongly believe that there is unique value that only we can deliver through our new Mission and Vision. We, the Miraca Group, will continuously strive to be a healthcare group that realizes “only one value.”

New Mission and Vision of the Miraca Group

Mission
Create new value in Healthcare and contribute to the prosperity of people.

Vision
Develop innovative diagnostic solutions to enhance trust in Healthcare and drive its evolution.

Bridging People to Healthcare

“A MESSAGE FROM TOP MANAGEMENT”

Shigekazu Takeuchi
Director, President and Group CEO

Miraca Holdings Inc.

Goki Ishikawa
President and CEO
Fujirebio Inc.

Shunichi Higashi
President and CEO
SRL, Inc.

The Origin of Group Name “Miraca”

“Miraca” is derived from its original concept “Looking ahead, we will remain committed and contribute to the development of science.” Miraca comes from abbreviating and combining two Japanese words: Mirai (future) and Ka(Ca)gaku (science).
Since its foundation in 1970, SRL has expanded its market share mainly in large hospitals, by providing esoteric tests, which require advanced technology.

We have provided sophisticated technology and academic knowledge to meet the needs of doctors at facilities including university hospitals and national hospitals. As a result, we have established strong relationships with medical institutions as a leader in the esoteric testing field. We leverage our expertise and laboratory structure to provide comprehensive testing services from esoteric and research testing to general and emergency testing for customers throughout Japan.

Providing Comprehensive Testing Services for Half a Century

A Broad Range of Services for In-Hospital Laboratories

SRL proposes a total solution that includes management services for in-hospital laboratories. Our goal is to help our customers improve the quality and efficiency of overall hospital operations by providing value-added consulting.

A Top Japanese Commercial Laboratory with a Nationwide Network

SRL carries out over 200 thousand tests each day from medical institutions nationwide. To secure test accuracy while shortening turnaround time, we have established a sample collection framework, utilizing our temperature-controlled sample transport boxes and original laboratory automation system. Moreover, we use our network of regional laboratories and sales offices to further enhance our community-based testing services.

Leading-Edge Healthcare Initiatives

In recent years we have been a leader in introducing advanced testing services including companion diagnostic-related testing and genomic analysis. We provide a range of testing services that support front-line healthcare. This includes precision medicine, which is a totally new diagnostic technique that uses personalized information such as patient genetic data.

Providing support for promotion of global pharmaceutical research and development

We provides comprehensive support to clinical studies and research, leveraging the specialist knowledge, highly advanced technical expertise, and domestic, Asian, and global networks that it has acquired through over 30 years of experience in full clinical trial testing support.

We provides high-quality services that ensure the accuracy of sample testing and traceability in the entire process from pre-clinical trial testing setups, to sample collection, laboratory deliveries, measurement, reporting of test results, and data control.

In collaboration with a CRO in the Miraca Group, the company provides full support to the entire clinical study and research process.
In Vitro Diagnostics

The LUMIPULSE® Series Has Supported Testing Sites for Over 25 Years

Fujirebio has been a leader in immunological testing in Japan since launching the world’s first serological reagents for syphilis in 1966. LUMIPULSE is a fully automated chemiluminescent enzyme immunoassay system. This high-quality, high-performance system has a broad and unique lineup of assay reagents, mainly for infectious diseases, cancers and lifestyle diseases. It is one of the reasons medical institutions and commercial laboratories have trusted us for over 25 years.

In 2017, the high-throughput LUMIPULSE L2400 was released on the Japanese market as an integrated testing instrument with a clinical chemistry analyzer, which contributes to a shorter turnaround time and increased efficiency for customers. Today, there are over 1,500 units of the LUMIPULSE series in operation, assisting medical institutions and clinical laboratories worldwide. Originating in Japan, LUMIPULSE has become a global immunoassay system brand.

Global Organization

The Miraca Group provides various products and services in more than 100 countries. Our U.S. subsidiary develops and manufactures world-class cancer testing products and supplies raw materials for diagnostic products. Our Belgian subsidiary develops and manufactures testing reagents for Alzheimer’s disease as a pioneer in the field. Furthermore, we established Fujirebio Holdings in 2017, which will oversee the entire in vitro diagnostics business. Through this new holding company, we will accelerate the execution of our global strategy to provide our world-leading product lineup.

Fujirebio is expanding its product line to encompass new diagnostic areas, on top of the immunology area. The fully automated blood coagulation analyzer, which we started marketing in Japan in 2016, is one example. With this product, we are able to contribute to the diagnosis of increasingly prevalent thrombotic diseases such as myocardial and cerebral infarction.

FusionPlus integrated LUMIPULSE® G1200 Plus

LUMIPULSES G800G

Lumipulse® reagents
Sterilization & Related services

Enhance the Efficiency of Hospital Operations with a One-Stop Total Solution

NIHON STERY provides services including both on-site and off-site sterilization outsourcing, surgical theater support (OP-Tek), endoscope sterilization & total support, medical equipment maintenance, and hospital supply procurement & logistics. Through these services, we support our customers' efforts to increase efficiency and the productivity of doctors and nurses.

To meet various customer needs as a medical partner, we focus on professional training and quality improvement to provide various services from our well-trained staff.

With an eye on both the present and the future, our goal is to be a leading total healthcare solution provider by addressing the increasingly sophisticated and diverse issues healthcare providers face in this super-aging society.

Emerging New Business & others

Food, environmental, and cosmetics testing services

Miraca Vitas promotes good health and well-being, and makes people's lives richer through the food, environmental, and cosmetics testing services it provides by applying reliable technical expertise and know-how developed by the Miraca Group in the medical field.

For the food testing services, we focus on nutrition analysis and microorganism tests as well as food allergen tests, genetic tests, and the development of functional foods. We will soon begin providing environmental and cosmetics testing services, and we will facilitate and automate a testing process and improve convenience for customers, who will be able to complete all transactions online, from making inquiries to obtaining test results and settling bills.

In addition to the existing testing services, we offer testing services with added value that meet customers' needs.

In-home care and nursing care equipment

Since its establishment following the implementation of the nursing care insurance program in 2000, Care’s has been engaged in home healthcare through its nursing care equipment wholesale business, and has provided support to nursing care equipment providers. Japan is experiencing a super aging population and has introduced a Community-based Integrated Care System that will play a pivotal role in its future healthcare services. In 2018, Care’s started to provide home visit nursing services, which is one of the main home healthcare services provided under the system. Leveraging experience in the nursing care equipment wholesale business, Care’s seeks to offer reassurance and reliability in home visit nursing care services, home visit elderly nursing care services, and in-home elderly nursing care support services, which are directly provided by the company. The Miraca Group is ready to embrace new challenges in pursuit of excellence in combining medical care and elderly nursing care.

Contact Research Organization (CRO)

With a high level of specialist knowledge and extensive experience in the clinical study and research field, SRL Medisearch, as a CRO, provides full support for testing administrative offices, case registration (EDC), monitoring, data management, statistical analysis, audit, and medical writing. We provide reliable and prompt coordination services for trial sponsors and site personnel in accordance with GCP, the Clinical Trials Act protocols, and SOPs.

We strive to be a reliable partner for pharmaceutical companies' new drug development and academia's new therapy research. In clinical trial testing collaborations, SRL Medisearch supports the development of new therapies as a comprehensive CRO which has analysis laboratories within its group.

Self-medication and health insurance society business

With Japan’s rapidly declining birthrate and aging population, as well as higher social security costs, the environment that surrounds medical care covered by health insurance is drastically changing, with change expected to accelerate even faster. To keep rising medical costs under control, the importance of early detection, care provided in a pre-symptomatic stage, prevention, and self-medication is more likely to be increasingly recognized.

Selmesta became a group company in February 2019. With health insurance societies, which are Selmesta’s main customers, as a main target, the Miraca Group offers solutions to control medical costs and provide self-medication support services to health insurance society members, making the best use of its technical expertise and know-how.
Our In Vitro Diagnostics business has bases in the United States, Europe and Asia, and supplies diagnostic products to over 100 countries. We established a joint venture in China to provide high-quality clinical laboratory testing services. The Miraca Group is continuously expanding its business globally, not only in Europe and North America but also in China and the Asian region.
### Research and Development

The Miraca Group is strengthening R&D to increase the value of the Group and achieve significant and sustainable medium- and long-term growth.

The establishment of Miraca Research Institute G.K. in July 2017 is one initiative. This company will promote basic research throughout the Group and collaborate with external companies and institutions, aiming to create new business and develop products and services – that will be our driver of future growth.

At the same time, our existing businesses will continue to develop and improve products and services to exceed customer expectations.

### Research Vision of Miraca Research Institute

The Miraca Research Institute aims to:

- Enhance the quality of products and services.
- Advance basic research.
- Foster innovation.
- Strengthen the group's research capability.
- Develop products and services.
- Collaborate with external companies and institutions.
- Create new businesses.

### Quality Control

The Miraca Group consistently enhances the quality of products and services.

**SRL**

SRL works to improve testing quality by continuously enhancing its quality management system.

- **1987** CAP Accreditation
- **2005** IS1890
- **2015** CLIA Certification

**Fujirebio**

Fujirebio conducts ongoing quality enhancement activities in order to secure the highest levels of product quality.

- **2001** ISO 13485

**Nihon Stery**

Nihon Stery has a quality management system in place at its sterilization centers in an effort to provide high quality services, ensure transparency in its activities, and improve its activity traceability records.

- **2003** ISO 9001

### Corporate Profile

**Corporate Name**
Miraca Holdings Inc.

**Headquarters**
Shinjuku Mitsui Building 8th Floor,
2-1-1 Nishishinjuku, Shinjuku-ku, Tokyo 163-0408
Tel: +81-3-5909-3335

**Director, President and Group CEO**
Shigekazu Takeuchi

**Established**
December 18, 1950
(Corporate name change and transition to a holding company structure through a corporate split on July 1, 2005)

**Capital Stock**
9,113 million yen (As of March 31, 2019)

**Employees** (Consolidated)
5,957 (As of March 31, 2019)

**Management Structure**
Company with three committees under the Companies Act of Japan

**Main Subsidiaries**
SRL, Inc. and Fujirebio, Inc. and Nihon STERY CO., LTD.